Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
A transposon and transposase system for human application Hackett PB; Largaespada DA; Cooper LJMol Ther 2010[Apr]; 18 (4): 674-83The stable introduction of therapeutic transgenes into human cells can be accomplished using viral and nonviral approaches. Transduction with clinical-grade recombinant viruses offers the potential of efficient gene transfer into primary cells and has a record of therapeutic successes. However, widespread application for gene therapy using viruses can be limited by their initially high cost of manufacture at a limited number of production facilities as well as a propensity for nonrandom patterns of integration. The ex vivo application of transposon-mediated gene transfer now offers an alternative to the use of viral vectors. Clinical-grade DNA plasmids can be prepared at much reduced cost and with lower immunogenicity, and the integration efficiency can be improved by the transient coexpression of a hyperactive transposase. This has facilitated the design of human trials using the Sleeping Beauty (SB) transposon system to introduce a chimeric antigen receptor (CAR) to redirect the specificity of human T cells. This review examines the rationale and safety implications of application of the SB system to genetically modify T cells to be manufactured in compliance with current good manufacturing practice (cGMP) for phase I/II trials.|*Genetic Vectors[MESH]|Animals[MESH]|Antigens, CD19/immunology[MESH]|Clinical Trials, Phase I as Topic[MESH]|Clinical Trials, Phase II as Topic[MESH]|DNA Transposable Elements/*genetics[MESH]|Genetic Therapy/*methods[MESH]|Humans[MESH]|Mice[MESH]|Plasmids[MESH]|Receptors, Antigen, T-Cell/*genetics/immunology[MESH]|Recombinant Fusion Proteins/genetics/immunology[MESH]|T-Lymphocytes/immunology/transplantation[MESH]|Transduction, Genetic/*methods[MESH]|Transposases/genetics/*metabolism[MESH] |
